Therapeutic Use of the Ketogenic Diet in Refractory Epilepsy: What We Know and What Still Needs to Be Learned
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data
OpenAlex W3080376907 · doi:10.3390/nu12092616
What was done
This narrative review synthesizes historical and clinical applications of the ketogenic diet and its modified variants (such as the modified Atkins diet and low-glycemic-index treatment) for refractory epilepsy, examining proposed mechanisms, clinical utility, and implementation barriers.
What was found
The abstract reports no primary quantitative data, sample sizes, or effect estimates. It qualitatively describes that ketogenic diets offer seizure protection in difficult-to-treat epilepsy by fundamentally shifting cerebral energy production from carbohydrates to fat.
Why it matters
Refractory epilepsy remains difficult to manage despite modern anti-seizure medications. Summarizing metabolic dietary strategies outlines alternative therapeutic pathways when standard pharmacotherapy fails.
Limits
The abstract provides no primary data, systematic search protocol, quantitative response rates, or safety metrics. The precise underlying mechanisms and real-world implementation hurdles remain incompletely characterized.
Cited by
- supports In 1921, Dr. Russell Wilder first introduced the ketogenic diet to manage epileptic seizures after observing that fasting reduced seizures.